Testimoni 4Life Transfer Factor
- Details
- Written by Super User
Bukan lagi orang per orang, tetapi sebuah negara, yaitu Russia yang memberikan testimoni tentang kehebatan produk 4Life Research.
Pada tahun 2004, Russian Academy of Medical Sciences (RAMS) melakukan penelitian yang mendalam tentang 4Life Transfer Factor. Pada akhir investigasi, mereka merilis sebuah Surat Metodologis, tidak hanya kuasa, tetapi mendorong profesional kesehatan di Rusia untuk menggunakan 4Life Transfer Factor dalam upaya mereka untuk mendukung sistem kekebalan tubuh atau sistem imun pasien mereka. 4Life Transfer Factor satu-satunya produk imunoterapi bukan obat yang pertama diresmikan pemakaiannya oleh Kementrian Kesehatan Rusia untuk digunakan di seluruh rumah sakit dan klinik di seluruh Rusia dan beberapa negara lain.
4Life® Transfer Factor™ Now Approved By the Health
Ministry of Russia for use in Hospitals and Clinics!
First Ever Dietary Supplement to be Approved for Use by Doctors and Hospitals in Russia
SANDY, UT (October 1, 2004) - In an unprecedented announcement in the history of network marketing, 4Life announced today that 4Life Transfer Factor products as immune modulators have been approved for use in hospitals and clinics in the Russian Federation. The results of ten separate clinical trials and two experimental studies on 4Life Transfer Factor products were combined in a Methodological Document that was approved by the Ministry of Health, which now allows doctors to recommend 4Life Transfer Factor Classic and 4Life Transfer Factor Plus® products to their patients.
First Dietary Supplement Approved for Use by Doctors and Hospitals in Russia
Commenting on this remarkable achievement, David Lisonbee, CEO of 4Life stated, “To my knowledge, this is the first time in the history of this industry that a network marketing company or any other dietary supplement company has had one of its dietary supplements approved for use in hospitals in Russia. The Russian Ministry of Health is the equivalent of the Food and Drug Administration in the United States. Doctors and scientists from Russia have been working jointly with scientists from 4Life for several years to arrive at this accomplishment. This approval establishes a new roll of dietary supplements in the Russian health care system.
Remarkable Response from Russian Academy of Medical Sciences
In another sector of research of 4Life Transfer Factor, Dr. Kisielevsky of the Russian Academy of Medical Sciences stated, “The 4Life sample [Transfer Factor Advanced Formula] activated NK (natural killer) cell activity more than the Interleukin-2 (IL2) drug we used as the standard.” This discovery has attracted the attention of The International Scientific and Technical Center (ISTC) of Russia.
Scientists from Several Countries Join Forces for Additional Clinical Studies of Transfer Factor
The ISTC of Russia is a member of a joint international project with other health agencies of Japan, Europe and the US. The objective of the international project is to combine efforts in finding improved immunotherapies. Following the discoveries from the NK cell testing, the scientists of 4Life have been invited to join the project. 4Life Transfer Factor as an immune modulator will be further researched in this international forum. The cost of the studies will be paid by the ISTC.
Worldwide Ramification
Speaking of this benchmark achievement, Dr. Calvin McCausland, VP of Research of 4Life, and Dr. Emma Oganova, 4Life/Eurasia President, jointly expressed that because of the acceptance by such a reputable organization and doctors from Russia and other major countries, 4Life Transfer Factor will gain wider acceptance in the professional and private sectors as a superior immune system enhancing product. The worldwide ramifications to this acceptance are just beginning.
4Life is the world’s foremost leader in the development, production and distribution of natural immune support products and was recently recognized by Inc. magazine as the fifteenth fastest growing privately-held company in America.
Penelitian Dr. Darryl See
Pada pasien kanker, 4Life Transfer Factor mampu meningkatkan fungsi sel Natural Killer, sel yang memerangi sel kanker
— Dr Darryl See —
Associate Clinical Professor W.H.O. ( World Health Organization) Western Europe, Dr. See received his degree from the University of California, Irvine. Academic appointments include: Assistant/Associate Clinical Professor of Medicine: Investigator, California Collaborative Treatment Group: and Infectious Disease Consultant, Liver Transplantation Service. He has received contracts, grants, and research awards from Harvard Biotechnology, Pfizer Pharmaceuticals, Upjohn Pharmaceuticals, Roche Molecular Systems,, National Institutes of Health, Department of Defense, and more.
Riset Dr Darryl See terhadap 20 pasien kanker stadium 4 menunjukan bahwa 16 pasien yang menjalani terapi 4Life Transfer Factor mengalami pemulihan dan dalam kondisi stabil. Dosis yang diberikan 9 kapsul 4Life Transfer Factor Plus per hari selama 6 bulan. Riset itu mencatat peningkatan fungsi NK-cell dari 6,4 menjadi 27,6 dan peningkatan Tumor Necrosis Factor alpha dari 12,4 menjadi 1287,5 pada bulan ke-enam. Riset ini menunjukkan bahwa rasio keberhasilan 4Life Transfer Factor pada terapi penyembuhan penyakit kanker mencapai 80%.
Video Testimoni Para Dokter, Orang Tua, Atlit, Umum & Pebisnis bisa anda saksikan link-link dibawah ini:
Study Penggunaan 4Life Transfer Factor pada berbagai Penyakit
Penyakit Epilepsi
Simko M, Mokrán V, Nyulassy S. Immunomodulatory therapy of epilepsy with transfer factor
[Article in Slovak]
Zdruzené lekársko-imunologické pracovisko Ustavu preventívnej a klinickej medicíny a Dérerovej Nemocnice a poliklinikou v Bratislave, Slovakia.
Effect of immunotherapy with Transfer factors administered for a period of three months was studied in a group of ten epileptic patients, treated with carbamazepine or primidon previously and throughout the study. Out of eight patients, who finished the study we could notice significant reduction of epileptic discharges in eight patients. The results of this study prove that addition of immunomodulatory treatment to patients with intractable epilepsy could substantially improve the course of the disease in some patients. (Tab. 1, Fig. 5, Ref. 13.)
PMID: 9264833 [PubMed - indexed for MEDLINE]
Penyakit Autis
- Kenneth Bock, MD. Transfer Factor Study with Autistic Children.
9 children
ages: 2.9-9.9
average age: 5.07
These children were given three capsules of Transfer Factor, three times daily, for three months. Each patient was assessed prior to the treatment, six weeks into the study, and at the completion of the three-month study. Dr. Bock used the Gilliam Autism Rating Scale for evaluation purposes. This method applies different scores based on: stereotyped "autistic" behaviors, communication, social interaction and developmental markers. These scores are then added together to determine an autism quotient. The higher the autism quotient is, the higher the degree of autism in the patient.
At the end of the three-month study, seven out of the nine autistic children had at least some improvement. Specifically, these improvements included:
* More attentive
* Eye contact improved
* Eczema improved
* Decreased incidence of illness
* Improved language skills
* Resolution of diarrhea
* Improved toileting skills
Although this study was small, Dr. Bock believes its results are very promising. He has included Transfer Factor as part of his treatment protocol and is excited about its possibilities for boosting the immune system in patients with autism as well as many other conditions he encounters on a daily basis.
Dr. Kenneth Bock is a physician who is renowned for his integrated approach to health and wellness. For the past 17 years he has integrated alternative modalities with conventional medicine into what he calls Progressive Medicine. He is the co-author of two books: The Road to Immunity and Natural Relief for your Child's Asthma. Dr. Bock recently conducted an important study on the use of Transfer Factor with children who have Autism Spectrum Disorders.
- Clinical observation of Dr. David Markowitz (Pediatrician)
"Some interesting observations from 4-5 kids with autism in our practice. All were started on transfer factors as a means to boost their immune system and hopefully keep them healthier. Well, that worked! But interestingly, all have shown better communication skills, better interactive skills, and less self-stimulatory behavior. Parents are delighted. Dr. Kenneth Bock in NY has seen similar observations. Amazing what a boosted immune system can do."
Dr. Markowitz is a pediatrician in Kennebunk, ME with a patient base of 4,500 children and has served as the Senior Pediatrician in a Private Pediatric Practice for 19 years. He received his Bachelor of Science degree from the University of Rochester in New York. He received his medical degree, general Pediatric training, and Pediatric Hematology/Oncology Fellowship from the University of Connecticut School of Medicine in Farmington, Connecticut.
Penyakit AIDS
- Study 1
Usage of transfer factors in treatment of HIV-Infected Patients
Granitov V.M., Karbysheva N.V., Sultanov L.V., McCausland C., Oganova E.
The Altay State Medical University; The Altay Regional Center for Prophylaxis and Treatment of AIDS, Russian Federation
Introduction: Included in this study were 25 HIV-infected patients (20 male and 5 female), ages 19 to 56 (15 patients ages 21-25). Individuals were classified according to V.I. Pokrovsky's classification (1989) for HIV-infection. Eight (8) patients were diagnosed to have stage 2B, thirteen (13) patients were stage 2C, three (3) patients were stage 3A and one (1) was stage 3B. Infection periods were as follows: nine (9) patients were infected 1 year ago, four (4) were 2 years ago, four (4) were three years ago, six (6) were 5 years ago and two (2) were 6 years ago.
Objective: The purpose of this study is to serve as an initial trial in evaluating the effects of enhanced transfer factors supplementation on HIV-infected patients.
Methodology: The experimental group (15 patients), who did not receive antiretroviral or immuno-correcting therapy, received enhanced transfer factors. They were administered one capsule twice a day for 7 days. The control group (10 patients) consisted of HIV-infected patients taking cycloferon in the following dosage schedule: 1st, 2nd, 4th, 6th, 8th, 10th, 12th and 14th days. Before treatment and 7 to 10 days after the treatment an evaluation was carried out to access the immune status of the patient groups and to determine cytokine (interleukin 1b (IL-1b), tumor necrosis factor (TNF-a) and g-interferon (IFN-g) levels.
Results: In the experimental group, it was found that after treatment with enhanced transfer factors there was an increase of lymphocytes in 13 patients, an in crease of CD3 cells in 15 patients, an increase of CD4 cells in 14 patients and an increase in CD8 cells in 12 patients. Immuno-regulating index (IRI) persisted on the same level in 3 patients was increased in 10 patients and decreased in 7 patients. IgG was reduced in 16 patients and IgM was within normal limits in all patients. An increase of IL-1b and IFN-7 was noted in all patients treated with transfer factors. Circulating Immune Complex (CIC) levels dropped to normal levels in 10 of the patients. In the control group an increase of lymphocytes was noted in only 3 patients. A decrease of CD3, CD4 and CD8 cells was noted in 6 patients. IRI persisted on the same level or decreased. CIC levels dropped to normal in 3 patients, increased in 6 patients, there was no change in 1 patient. The occurrence of increases and decreases of IgG were equal.
Conclusion: We conclude that transfer factors therapy considerably improves the immune status of HIV-infected patients and can be recommended in combating the pathogenesis of the disease. Further studies are needed to determine optimal therapy, the necessity to repeat courses of the treatment and the frequency of therapy needed.
- Study 2
Treating AIDS patients with HIV-Specific Transfer Factor
Biotherapy 9: 41-7 (1996)
H. Hugh Fudenberg,1 Giancarlo Pizza,2 F. Raise,3 F. Gritti,3 F. Chiodo,2 C. DeVinci,2 Dimitri Viza.4
1. NeuroImmuno Therapeutics Research Found., Spartanburg SC 29303;
2. Osp. Malpighi, 40138 Bologna, Italy;
3. Osp. Maggiore, Bologna, Italy;
4. Université de Paris V, Faculté de Médecine, 75270 Paris, France.
Rationale: Specific transfer factor (TF) is known to be effective in treating viral infections and preliminary studies with AIDS patients and SIV-infected macaques have produced encouraging observations.
Methods: TF was made from immunized BALB/c mice. Its activity was tested in vitro, and it was orally administered to AIDS patients with <500 CD4 lymphocytes.
Results: 20 AIDS patients, treated with TF and zidovudine (ZDV) for more than 6 months, showed improvement or stabilization of their clinical condition and/or biological parameters. Four patients with a survival prognosis of 6 months have so far survived for more than 4 years. In one patient, a regression of KS and voluminous plantar warts was noticed. Skin tests became positive in 9/12 anergic patients. Furthermore, data in 5 patients suggest that TF may activate the Th/1 cytokine secretion pattern. Three other patients had PCR's that dropped from 268,000/mm3 to 24,000/mm3; 100,000/mm3 to 2,000/mm3; and 80,000/mm3 to 0.
Conclusion: HIV specific TF can be beneficial even in advanced AIDS patients. Further studies should determine whether treatment could indefinitely arrest disease progression. TF may also be able to prevent retroviral infections; and as a prophylactic vaccine (as in the case of VZV infections in immunocompromised leukemic children), it should be further investigated in animal models.
Rheumatoid Arthritis
Georgescu C, Effect of long-term therapy with transfer factors in rheumatoid arthritis.
Specific immunotherapy with transfer factors was used in a chronic experiment in a group of 50 female patients with rheumatoid arthritis (RA) stage I-III. The patients were followed up for 24 months, clinical and biologic examinations being repeated every 3 months. In this period the patients received beside the basic nonsteroid anti-inflammatory therapy, one unit transfer factors every week over a period of 6 months then one until transfer factors every month (10 patients) to the end of experiment. Of the 50 patients 15 (30%) did not respond to the therapy and the experiments had to be interrupted after 6 months. Excellent, very good and good results were obtained in 35 patients (70%). In 12 patients the response was good but the dose of transfer factors had to be increased to two units/week in the first 6 months. In 13 patients the results obtained were very good and therapy with nonsteroid products + transfer factors was continued even after the first 6 months. In 10 patients with RA stage I the results obtained were excellent and after 6 months the nonsteroid therapy could be interrupted and the therapy was continued only with one unit transfer factors every month. The study confirmed the fact that specific immunotherapy with transfer factors represents an important adjuvant in the treatment of rheumatoid arthritis (RA).
